Aug 12, 2022 / 03:00AM GMT
Operator
Good morning, ladies and gentlemen. Welcome to the Q1 FY '23 Earnings Conference Call of Glenmark Pharmaceuticals Limited. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Utkarsh Gandhi, General Manager, Investor Relations for Glenmark Pharmaceuticals. Thank you. And over to you, sir.
Utkarsh Gandhi -
Thank you, moderator. Good morning, everyone, and a very warm welcome to the Q1 FY '23 Results Conference Call of Glenmark Pharmaceuticals Limited.
Before we start the call, a review of the operations for the first quarter of FY '23. Glenmark's consolidated revenue from operations for Q1 FY '23 was at INR 27,773 million as against INR 29,649 million in the corresponding quarter last year, recording a decrease of 6.3%. Excluding the global sales of COVID-related products in the first quarter of FY '22, the year-on-year growth in the base business in the current financial year was at 10.4%.
Let's review the performance of the formulation business, starting with India. Sales for the
Q1 2023 Glenmark Pharmaceuticals Ltd Earnings Call Transcript
Aug 12, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers